Meanwhile, inhibitors of the IL-6/STAT3 signaling pathway should be promoted, and the efficacy and safety of these targeted inhibitors should be evaluated, it is need to formulate the standardization of clinical individualization treatment for liver cancer. The gene discussed is STAT3; the disease is liver cancer.